

Because kidney and liver transplants are no longer subject to the Research Criteria, NIH plans to retain these outcomes only where applicable (e.g., for deceased donor heart-living donor kidney transplants, deceased donor heart-living donor liver transplants, and for other organs subject to the Research Criteria).

Transplant Recipients: NIH has added several additional data elements and outcome measures to those included for transplant recipients in the 2015 Research Criteria. NIH has added the following outcome measures: type of rejection (antibody mediated versus cellular rejection), chronic allograft vasculopathy (heart), chronic lung allograft dysfunction (lung), hospital infections, estimated glomerular filtration rate (heart and lung), HIV superinfection, graft failure (heart and lung), re-transplantation, and simultaneous multiple organ transplants.

While not included as a requirement of the Research Criteria, NIH has included the following recommendation regarding patient management:

NIH recommends that transplant programs and healthcare providers follow current and updated practice management guidelines. For specific guidance, transplant programs and healthcare providers should consult vaccination guidance (<https://www.cdc.gov/acip-recs/hcp/vaccine-specific/index.html>) and expert guidance for the management of patients with HIV pre-, during-, and post-transplant summarized in: Transplantation in people with HIV (<https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/whats-new>).

References

1. Department of Health and Human Services (DHHS). Human Immunodeficiency Virus (HIV) Organ Policy Equity (HOPE) Act Safeguards and Research Criteria for Transplantation of Organs Infected With HIV. 80 FR 34912. June 18, 2015.
2. Doberne J.W., et al. (2021). Heart transplantation survival outcomes of HIV positive and negative recipients. *Annals of Thoracic Surgery*, 111:1465–71.
3. Durand C., et al. (2024). Safety of kidney transplantation from donors with HIV infection. *N Engl J Med*, 391:1390–401.
4. HIV Organ Policy Equity (HOPE) Act of 2013. Public Law 113–51.
5. Kern, R., Seethamraju, H., Blanc, P., Sinha, N., Loebe, M., Golden, J., et al. (2014). Lung Transplantation in HIV Seropositive Patients. *Chest*, 145(3 Suppl), 642A.
6. Koval C., et al. (2018). Heart and lung transplantation outcomes in HIV-positive recipients.
7. Koval, C.E., Farr, M., Krisl, J., Haidar, G.,

Pereira, M.R., Shrestha, N., Malinis, M.F., Mueller, N.J., Hannan, M.M., Grossi, P., & Huprikar, S. (2019). Heart or lung transplant outcomes in HIV-infected recipients. *The Journal of heart and lung transplantation: the official publication of the International Society for Heart Transplantation*, 38(12), 1296–1305. <https://doi.org/10.1016/j.healun.2019.09.011>.

8. Madan S., et al. (2019). Outcomes of heart transplantation in patients with human immunodeficiency virus. *Am J Transplant*. 19:1529–35.
9. Rouzard C., et al., (2022). Lung transplantation in HIV-positive patients: a European retrospective cohort study. *Eur Respir J*. 60(1):2200189.
10. Storm, K., & Durand, C.M. (2024). Overcoming barriers and stigma: new frontiers in solid organ transplantation for people with HIV. *Clinical microbiology reviews*, 37(1), e0011122. <https://doi.org/10.1128/cmr.00111-22>.
11. Wairimu, F., Ward, N.C., Liu, Y., & Dwivedi, G. (2021). Cardiac Transplantation in HIV-Positive Patients: A Narrative Review. *Journal of acquired immune deficiency syndromes (1999)*, 87(2), 763–768. <https://doi.org/10.1097/QAI.0000000000002647>.

Dated: December 20, 2024.

Lawrence A. Tabak,

Principal Deputy Director, National Institutes of Health.

[FR Doc. 2024–31265 Filed 12–27–24; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of General Medical Sciences; Notice of Closed Meeting

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of General Medical Sciences Special Emphasis Panel Review of Centers of Biomedical Research Excellence (COBRE) Phase III-Translational Centers (P30) Applications

Date: March 18–19, 2025

Time: 10:00 a.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications

Address: National Institutes of Health, National Institute of General Medical Sciences, Natcher Building, 45 Center Drive, Bethesda, Maryland 20892.

Meeting Format: Virtual Meeting.

Contact Person: Manas Chattopadhyay, Ph.D., Scientific Review Officer, Office of Scientific Review, National Institute of General Medical Sciences, National Institutes of Health, 45 Center Drive, Room 3AN12N, Bethesda, Maryland 20892, 301–827–5320, manasc@mail.nih.gov.

(Catalogue of Federal Domestic Assistance Program No. 93.859, Biomedical Research and Research Training, National Institutes of Health, HHS)

Dated: December 19, 2024.

Miguelina Perez,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2024–30873 Filed 12–27–24; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Office of the Secretary; Notice of Meeting

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting of Interagency Autism Coordinating Committee.

The meeting will be virtually held and is open to public viewing. The connection information and how to access the meeting will be available on the IACC website <https://iacc.hhs.gov/meetings/iacc-meetings/2025/summary-of-advances/january14/>. Advanced registration is recommended. Individuals wishing to participate virtually that need special assistance or other reasonable accommodations should submit a request to the Contact Person listed on this notice at least seven (7) business days prior to the meeting.

The purpose of the IACC meeting is to discuss the committee's nominations of articles for the *2024 IACC Summary of Advances in Autism Research* report. The final report will summarize the top 20 advances in autism biomedical and services research, as selected by the IACC.

Name of Committee: Interagency Autism Coordinating Committee 2024 IACC Summary of Advances in Autism Research.

Date: January 14, 2025.

Time: 2:00 p.m. to 4:00 p.m.